OnDemand
State of the Heart 2022
  • Detail & Program Access
  • Overview & Objectives
  • Credit Eligibility
  • Agenda
  • Program Materials
  • Funding Support
View Session 1

View Session 2

View Session 3

Program Access and Details:

Program Length:
90 minutes x 3

Resources:
DOWNLOADABLE SLIDES. View the Program Materials tab for more information.

Credits:
The OnDemand version of this program is not accredited. Physicians may earn self-learning credits through active steps. View more information under the Credit Eligibility tab.

Target Audience:
Family physicians, cardiovascular specialists, allied health professionals

 

State of the Heart 2022

View Session 1

View Session 2

View Session 3

Program Access and Details:

Program Length:
90 minutes x 3

Resources:
DOWNLOADABLE SLIDES. View the Program Materials tab for more information.

Credits:
The OnDemand version of this program is not accredited. Physicians may earn self-learning credits through active steps. View more information under the Credit Eligibility tab.

Target Audience:
Family physicians, cardiovascular specialists, allied health professionals

 

State of the Heart 2022

SESSION 1 - LEARNING OBJECTIVES

  • Explore current role of GLP-1 agonists in clinical practice
  • Recognize the impact of kidney protection for cardiac protection
  • Determine when to use medical vs surgical treatment in stable CAD
  • Describe appropriate antiplatelet therapy for stable CAD patients

SESSION 2 - LEARNING OBJECTIVES

  • Describe a guidelines centric approach to manage and support patients with obesity
  • Distinguish the appropriate use of ezetimibe or PCSK9 inhibitors in secondary prevention
  • Discuss the role of a new market entrance in lipid management
  • Apply guideline centric strategies for managing cardiovascular risk beyond LDL-C

SESSION 3 - LEARNING OBJECTIVES

  • Summarize the benefits and challenges with using DOAC’s
  • Describe appropriate management strategies and therapies for managing patients with HFrEF and HFpEF
  • Explore developments in cardiovascular medicine that may change how we treat patients in the future

The OnDemand recordings of this live program are NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio. 

Program Chapter
Presenter
SESSION ONE
GLP-1 agonists: underused and underappreciated?
Darren McGuire
CKD: save the kidneys, save the heart
David Cherney
Stable CAD: when to use antianginals and when to revascularize
Tara Sedlak
Stable CAD: ASA alone, prolonged DAPT or low-dose rivaroxaban?
Marc S. Sabatine
SESSION TWO
Have we entered a new era in obesity management?
Megha Poddar
When to use ezetimibe or PCSK9 inhibitors in secondary prevention
Jacques Genest
Inclisiran: the new LDL kid on the block
Milan Gupta
Cardiovascular risk reduction: more than just LDL-C
Deepak Bhatt
SESSION THREE
Lessons learned after a decade of experience with DOAC’s
Paul Dorian
HFrEF: how to start and titrate the four pillars of treatment
Nadia Giannetti
HFpEF: which drugs have become standard of care?
Milan Gupta
CV medicine in the next decade: predicting the future
Deepak Bhatt

Program slides:

This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization.  A PDF copy of the slides from this program is available for CCRN members of the CCRN website. Visit www.ccrnmd.com/resources to download the materials.

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and was supported through an educational grant received from Gold: HLS Therapeutics; Silver: AstraZeneca, Bayer, BMS/Pfizer Alliance, Boehringer Ingelheim, Janssen, KYE Pharmaceuticals, Sanofi and in-kind support from Pfizer.